The development of antiviral therapy and vaccines against respiratory syncytial virus and human parainfluenza virus type 3

International Journal of Pharmaceutical Medicine

Volumn 15, Issue 4, 2001, Pages 175-190

  Josey, Elizabeth A ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Antivirals; Parainfluenza virus; Respiratory infections; Respiratory syncytial virus; Vaccines

Indexed keywords

ANTIVIRUS AGENT; DNA VACCINE; LIVE VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEART DISEASE; HUMAN; IMMUNE DEFICIENCY; LOWER RESPIRATORY TRACT INFECTION; LUNG DISEASE; MORBIDITY; MORTALITY; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINATION;

EID: 0034802340     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124363-200108000-00004     Document Type: Article

References (129)

1. Detection and characterisation of proteins encoded by the second ORF of the M2 gene of pneumoviruses
2. + T cells
3. Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats
4. Respiratory syncytial virus immune globulin intravenous: Indications for use
5. Neutralisation of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies
6. The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication
7. A recombinant human parainfluenza virus Type 3 in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates
8. Phenotypic consequences of rearranging the P, M and G genes of vesicular stomatitis virus
9. Efficacy of passively administered monoclonal antibodies against respiratory syncytial virus infection in cotton rats
10. Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses
11. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes
12. Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection
13. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation
14. Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na
15. Protection of cotton rats against human parainfluenza virus type 3 by vaccination with a chimeric FHN glycoprotein
16. The guinea pig as a model for the study of maternal immunisation against respiratory syncytial virus infections in infancy
17. Safety and tolerance of nebulised ribavirin in clinical usage
18. A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1
19. Development of a parainfluenza virus type 1,2,3 subunit vaccine
20. Inhibitory effect of pyridobenzazoles on virus replication in vitro
21. Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus
22. Interferon action against human parainfluenza virus type 3: Involvement of a novel antiviral pathway in the inhibition of transcription
23. Targeting RNA decay with 2′,5′ oligoadenylate-antisense in respiratory syncytial virus-infected cells
24. Enhanced pulmonary histopathology induced by respiratory syncytial virus challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10
25. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
26. Children's respiratory viral diseases treated with interferon aerosol
27. Inhibition of respiratory syncytial virus-host cell interactions by mono- and diamidines
28. Respiratory syncytial virus vaccines
29. Parainfluenza virus 3 infection after stem cell transplant: Relevance to outcome of rapid diagnosis and ribavirin treatment
30. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected RSV infection
31. Comparative analysis of immunostimulatory properties of different adjuvants on the immunogenicity of a prototype parainfluenza virus type 3 subunit vaccine
32. Prospects for a parainfluenza virus vaccine
33. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60
34. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalised elderly
35. Biochemistry and clinical applications of ribavirin
36. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro
37. Priming immunisation determined T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus
38. Respiratory syncytial virus infection in anti-mu-treated mice
39. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum
40. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The RSVIG study group
41. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia
42. Combined immunoprophylaxis and ribavirin therapy of respiratory syncytial virus in the cotton rat
43. Prospects for a respiratory syncytial virus vaccine
44. Protection of cotton rats by immunisation with the human parainfluenza virus type 3 fusion (F) glycoprotein expressed on the surface of insect cells infected with a recombinant baculovirus
45. Expression of the surface glycoprotein of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector
46. The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription
47. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children
48. Concurrent circulation of antigenically distinct strains of respiratory syncytial virus during community outbreaks
49. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3
50. Immunogenicity of recombinant adenovirus-respiratory syncytial virus using Ad4, Ad5 and Ad7 vectors in dogs and a chimpanzee
51. Prevention of rhinovirus infection in chimpanzees by soluble intercellular adhesion molecule-1
52. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides
53. Recombinant human respiratory syncytial virus from cDNA and construction of subgroup A and B chimeric RSV
54. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: Extensive sequence divergence between antigenically related proteins
55. Direct comparison of the activities of two humanised respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19
56. Development of a humanised monoclonal antibody (MEDI-4930 with potent in vitro and in vivo activity against respiratory syncytial virus
57. Long-term maintenance of B cell immunity to influenza virus hemagglutinin in mice following DNA-based immunization
58. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic and phenotypically stable in infants and children
59. Design of potent selective zinc-mediated serine protease inhibitors
60. Inhibitory effects of several antiviral compounds on the replication of respiratory syncytial virus in vitro
61. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
62. Safety and antigenicity of temperature-sensitive mutant respiratory syncytial virus in infants and children
63. Respiratory syncytial virus immunology
64. Heparin-dependent attachment of respiratory syncytial virus to host cells
65. Peptides from conserved regions of paramyxovirus fusion proteins are potent inhibitors of viral fusion
66. Comparison of soluble and secreted forms of human parainfluenza virus type 3 glycoproteins expressed from mammalian and insect cells as subunit vaccines
67. Respiratory disease due to Parainfluenza virus in adult bone marrow transplant recipients
68. Protection against respiratory syncytial virus infection by DNA immunization
69. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon
70. Live-attenuated vaccines against respiratory syncytial virus: Molecular analysis and construction by reverse genetics
71. Respiratory syncytial virus: Recent progress towards the discovery of effective prophylactic and therapeutic agents
72. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus in infants and young children at risk for severe RSV disease
73. Dissociation between serum neutralising and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine
74. New approaches to the use of ribavirin
75. Differential antiviral activity of derivatised dextrans
76. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalisation for lower respiratory tract illness in very low birth weight infants
77. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitised to the major surface glycoprotein G
78. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model
79. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. The Impact-RSV Study Group
80. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24-48 months old
81. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3
82. Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA
83. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment
84. Reduction of respiratory syncytial virus hospitalisation among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
85. Respiratory syncytial virus antiviral agents
86. An update on respiratory syncytial virus antiviral agents
87. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat
88. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats
89. Advances in prevention of respiratory syncytial virus infections
90. Intranasal immunization of hamsters with envelope glycoproteins of human parainfluenza virus type 3
91. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children
92. Respiratory syncytial virus immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: The RSVIG study group
93. The development of monoclonal antibodies to respiratory syncytial virus and their use in diagnosis by indirect immunofluorescence
94. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV-3 in primates
95. Recombinant bovine/human parainfluenza virus type 3 expressing the respiratory syncytial virus G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV-3
96. Infectious rabies viruses from cloned cDNA
97. The epidemiology of acute respiratory tract infection in young children: Comparasion of findings from several developing countries
98. The interferon system: A bird's eye view of its biochemistry
99. Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses
100. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin
101. Respiratory syncytial virus infection
102. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease
103. Monoclonal antibodies protect against respiratory syncytial virus infection in mice
104. Suppression of respiratory syncytial virus infection in cotton rats by bis(5-amidino-2-benzimidazolyl)methane
105. Aromatic amidines - Comparison of their ability to block respiratory syncytial virus-induced cell-fusion and to inhibit plasmin, urokinase, thrombin and trypsin
106. Attenuation of bPIV-3 in nonhuman primates and its ability to confer immunity to hPIV-3 challenge
107. RSV infections: Developments in the search for new drugs
108. DNA vaccines
109. Novel pathways in the pathogenesis of respiratory syncytial virus disease
110. Small-particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice
111. Monoclonal antibodies to respiratory syncytial virus proteins: Identification of the fusion protein
112. Novel anti-respiratory syncytial viral compounds: Benzodithiin derivatives
113. Monoclonal antibodies for prevention and treatment of respiratory syncytial virus infection
114. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice
115. Parainfluenza virus respiratory infection after bone marrow transplantation
116. Combination therapy with aerosolised ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients
117. Addition of a missense mutation present in the L gene of respiratory syncytial virus cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity
118. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees
119. Inhibition of respiratory syncytial virus replication in vitro by a pyrazole dicarboxamide analogue of ribavirin
120. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro
121. Mode of action of ribavirin: Effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis
122. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children
123. Evaluation of a live, cold-passaged termperature-sensitive, respiratory syncytial virus vaccine candidate in infancy
124. Respiratory syncytial virus disease and prospects for its control
125. Evaluation of the toxicity and antiviral activity of carbocyclic-3-deazadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats
126. Toxicity and antiviral activity of LY-253963 against respiratory syncytial virus and parainfluenza type 3 virus in tissue culture and in cotton rats
127. CL-387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats